3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
230
Breast Neoplasms
187
Ovarian Neoplasms
113
Neoplasms
100
Neoplasm Metastasis
59
Lung Neoplasms
54
Fallopian Tube Neoplasms
47
Triple Negative Breast Neoplasms
44
Stomach Neoplasms
41
Parkinson Disease 4, Autosomal Dominant Lewy Body
41
Endometrial Neoplasms
37
Carcinoma, Ovarian Epithelial
32
Squamous Cell Carcinoma of Head and Neck
28
Uterine Cervical Neoplasms
24
Esophageal Neoplasms
21
Carcinoma
21
Colorectal Neoplasms
20
Recurrence
19
Melanoma
18
Esophageal Squamous Cell Carcinoma
18
Small Cell Lung Carcinoma
16
Pancreatic Neoplasms
16
Head and Neck Neoplasms
14
Solid Tumors
12
Adenocarcinoma
12
Advanced Solid Tumors
11
Carcinoma, Renal Cell
10
Carcinoma, Squamous Cell
9
Urinary Bladder Neoplasms
8
Solid Tumor
8
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Paclitaxel
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts